Famed Weight Loss Drug Wegovy by Novo Nordisk Sees Significant Drop In Long-Term Use, Study Reveals
Portfolio Pulse from Vandana Singh
A study reveals that only 32% of patients prescribed Novo Nordisk's weight-loss drug, Wegovy, were still using the medication a year after their initial prescription, indicating a significant drop in adherence. The average annual cost of care for patients increased by 59% after starting the medication. The study was conducted by Prime Therapeutics, a pharmacy benefits manager, reviewing data for 4,255 people. NVO shares are up 0.71% at $153.33 during the premarket session on the last check Wednesday.
July 12, 2023 | 12:14 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Novo Nordisk's weight-loss drug, Wegovy, sees a significant drop in long-term use, potentially impacting the company's revenues. Despite this, NVO shares are up 0.71%.
The significant drop in long-term use of Wegovy could potentially impact Novo Nordisk's revenues from the drug. However, the impact on the stock price is not clear as the shares are currently up. The situation needs to be monitored closely for any potential impact.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100